The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis.
baricitinib results in decreased activity of JAK1 protein baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]
baricitinib results in decreased activity of JAK2 protein baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]
baricitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased expression of SAA1 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased expression of SAA2 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]
browse the term
